Higher Olive Oil Intake Tied to Lower Risk for Dementia-Related Death
By Lori Solomon HealthDay Reporter
WEDNESDAY, May 8, 2024 -- Higher olive oil intake is associated with a lower risk for dementia-related mortality in U.S. adults, according to a study published online May 6 in JAMA Network Open.
Anne-Julie Tessier, Ph.D., from the Harvard T.H. Chan School of Public Health in Boston, and colleagues examined the association between olive oil intake and subsequent risk for dementia-related death, as well as the joint association with diet quality and substitution for other fats. The analysis included data from 92,383 participants in the Nurses' Health Study (1990 to 2018) and Health Professionals Follow-Up Study (1990 to 2018).
The researchers found that individuals who were homozygous for the apolipoprotein ε4 (APOE ε4) allele were five to nine times more likely to die with dementia. Consuming at least 7 g/day of olive oil was associated with a lower risk for dementia-related death (adjusted pooled hazard ratio, 0.72) versus never or rarely consuming olive oil. When adjusting further for APOE ε4, results were similar. There was no interaction by diet quality scores. Replacing 5 g/day of margarine or mayonnaise with the equivalent amount of olive oil was associated with an 8 to 14 percent lower risk for dementia mortality. There was no significant reduction in risk for substitutions for other vegetable oils or butter.
"Beyond heart health, the findings extend the current dietary recommendations of choosing olive oil and other vegetable oils for cognitive-related health," the authors write.
Two authors disclosed ties to the pharmaceutical industry.
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted May 2024
Read this next
Mean Cost of Bringing New Drug to U.S. Market Is $879.3 Million
TUESDAY, July 2, 2024 -- The mean cost of developing a new drug for the U.S. market is estimated to be $879.3 million when both drug development failure and capital costs are...
Patient–Primary Care Provider Language Concordance Tied to Better Outcomes
TUESDAY, July 2, 2024 -- Patient-family physician language concordance is associated with a lower risk for adverse outcomes, according to a study published online June 3...
Self-Administered Gerocognitive Exam Improves Detection of Cognitive Issues in Primary Care
TUESDAY, July 2, 2024 -- A self-administered gerocognitive examination (SAGE) is easily incorporated into primary care provider (PCP) visits, and its use significantly increases...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.